Literature DB >> 10953271

Emerging indications for permanent pacing.

D L Wolbrette1, G V Naccarelli.   

Abstract

New indications for pacing are being investigated in the areas of vasovagal syncope, hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, and atrial fibrillation. It is hoped that pacing will offer an alternative therapy to patients who are refractory to medical therapy. Although pacing for vasovagal syncope continues to be controversial, it appears that a highly symptomatic group with a predominately cardioinhibitory component can benefit. Current data indicate that dual-chamber pacing should not be considered therapeutically equal to septal myectomy in patients with hypertrophic obstructive cardiomyopathy, but may be considered in those more than 65 years of age, or in others who are not good surgical candidates. Biventricular or left ventricular pacing appears promising in heart failure patients and may be combined with implantable cardioverter-defibrillator therapy. Lead technology for coronary vein placement needs further improvement. Dual-site atrial pacing appears to help prevent recurrences of atrial fibrillation and may become a useful adjunct to drug, ablative, and implantable cardioverter-defibrillator therapies.

Entities:  

Mesh:

Year:  2000        PMID: 10953271     DOI: 10.1007/s11886-000-0093-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  39 in total

1.  Dual chamber pacing for neurally mediated syncope with a prominent cardioinhibitory component.

Authors:  C P Shah; R K Thakur; B Xie; P Pathak
Journal:  Pacing Clin Electrophysiol       Date:  1999-07       Impact factor: 1.976

2.  The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope.

Authors:  S J Connolly; R Sheldon; R S Roberts; M Gent
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

3.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

Authors:  H Seggewiss; U Gleichmann; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

Review 4.  Has the survival of the heart failure population changed? Lessons from trials.

Authors:  J G Cleland; A Clark
Journal:  Am J Cardiol       Date:  1999-03-11       Impact factor: 2.778

5.  Evaluation of left ventricular based pacing in patients with congestive heart failure and atrial fibrillation.

Authors:  Y Etienne; J Mansourati; M Gilard; V Valls-Bertault; J Boschat; D G Benditt; K G Lurie; J J Blanc
Journal:  Am J Cardiol       Date:  1999-04-01       Impact factor: 2.778

6.  Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points.

Authors:  S R Ommen; R A Nishimura; R W Squires; H V Schaff; G K Danielson; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

7.  Clinical experience with Thera DR rate-drop response pacing algorithm in carotid sinus syndrome and vasovagal syncope. The International Rate-Drop Investigators Group.

Authors:  D G Benditt; R Sutton; M D Gammage; T Markowitz; J Gorski; G A Nygaard; J Fetter
Journal:  Pacing Clin Electrophysiol       Date:  1997-03       Impact factor: 1.976

8.  Improvement of cardiac function in patients with severe congestive heart failure and coronary artery disease by dual chamber pacing with shortened AV delay.

Authors:  A Auricchio; L Sommariva; R W Salo; A Scafuri; L Chiariello
Journal:  Pacing Clin Electrophysiol       Date:  1993-10       Impact factor: 1.976

9.  Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy.

Authors:  X Jeanrenaud; J J Goy; L Kappenberger
Journal:  Lancet       Date:  1992-05-30       Impact factor: 79.321

10.  VDD pacing at short atrioventricular intervals does not improve cardiac output in patients with dilated heart failure.

Authors:  D Innes; J W Leitch; P J Fletcher
Journal:  Pacing Clin Electrophysiol       Date:  1994-05       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.